高级搜索
非小细胞肺癌患者血清RUNX3基因异常甲基化的检测及意义[J]. 肿瘤防治研究, 2011, 38(06): 671-674. DOI: 10.3971/j.issn.1000-8578.2011.06.016
引用本文: 非小细胞肺癌患者血清RUNX3基因异常甲基化的检测及意义[J]. 肿瘤防治研究, 2011, 38(06): 671-674. DOI: 10.3971/j.issn.1000-8578.2011.06.016
Significance of RUNX3 Hypermethylation in Serum DNA of Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 671-674. DOI: 10.3971/j.issn.1000-8578.2011.06.016
Citation: Significance of RUNX3 Hypermethylation in Serum DNA of Non-small Cell Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 671-674. DOI: 10.3971/j.issn.1000-8578.2011.06.016

非小细胞肺癌患者血清RUNX3基因异常甲基化的检测及意义

Significance of RUNX3 Hypermethylation in Serum DNA of Non-small Cell Lung Cancer Patients

  • 摘要: 目的探讨非小细胞肺癌患者血清中runt相关转录因子3 (runt-related transcription factor 3,RUNX3)基因启动子区域甲基化状况及其临床意义。方法甲基化特异性聚合酶链反应(methylation-specific polymerase chain reaction, MSP)法检测62例NSCLC和30例肺部良性疾病患者和16例健康体检者血清中RUNX3启动子区域甲基化状况,并分析其与临床特征的关系。结果RUNX3甲基化检出率在NSCLC患者为40.32%(25/62),而肺部良性疾病患者和健康体检者血清未检出(Fisher精确检验,P<0.05)。NSCLC患者血清RUNX3基因甲基化在腺癌检出率高于鳞癌(51.43% vs. 25.93%,χ2=4.12,P<0.05),Ⅰ~Ⅱ期甲基化检出率(8/11 ,72.73%)高于Ⅲ~Ⅳ期(17/51, 33.33%),与NSCLC患者性别、年龄、吸烟指数、分化程度无明显相关(P>0.05)。结论RUNX3异常甲基化可能在NSCLC发生、发展中起重要作用,有望成为NSCLC辅助诊断的分子标志。

     

    Abstract: ObjectiveTo detect the promoter hypermethylation status of runt-related transcription factor 3 (RUNX3) gene in serum DNA of non-small cell lung cancer patients and to discuss its clinical significance. MethodsSerum DNA was extracted from 62 patients with NSCLC 30 patients with benign pulmonary disease, and 16 health subjects with medical check-up.The methylation status of RUNX3 gene was detected by MSP and the correlation of methylation profiles with clinical characteristic was statistically analyzed. ResultsAberrant promoter methylation of RUNX3 was found in 25 of 62 (40.32%) NSCLC patients,but in none of patients with benign pulmonary disease and health subjects with medical check-up(Fisher exact probabilities test,P<0.05). The promoter hypermethylation of RUNX3 correlated with histopathology (χ2=4.12,P<0.05)and clinical stages(Fisher exact probabilities test,P<0.05),but not with age,gender,smoking index or differentiation in NSCLC patients. ConclusionThe promoter hypermethylation of RUNX3 may play an important role in the tumorigenesis and progression. It is hopeful to become a promising novel biomarker for diagnosis in NSCLC.

     

/

返回文章
返回